Pharmafile Logo

onartuzumab

- PMLiVE

Novartis announces positive phase 3 trial results for advanced oesophageal cancer

Results from the study showed tislelizumab plus chemotherapy significantly improved overall survival for patients, regardless of PD-L1 status

- PMLiVE

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia

The recommendation makes Scemblix the first treatment in its class to be authorised in Britain

- PMLiVE

CureVac to acquire Frame Cancer Therapeutics in €32m deal

The acquisition will advance CureVac’s oncology strategy and offers the potential to develop off-the-shelf and personalised cancer vaccines

- PMLiVE

EC approves Roche’s Tecentriq for early-stage lung cancer

Tecentriq has now become the first cancer immunotherapy approved in Europe for the treatment of certain types of early-stage NSCLC

Part 3 of the Medscape video series #EHA

Ahead of  Europe’s largest hematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer, interviews Dr. Naval Daver on the most important abstracts to look out for in Myeloid and...

Medscape Education Global

Part 2 of the Medscape video interview series

Ahead of Europe’s largest haematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer interviews Dr. John Gribben on the most important abstracts to look out for in CLL and the...

Medscape Education Global

- PMLiVE

Roche’s Polivy receives EC approval for lymphoma therapy

The combination therapy is for patients with previously untreated diffuse large B-cell lymphoma

Roche Basel Switzerland

Roche collaborates with Global Fund to strengthen critical diagnostics infrastructure

The partnership is focused on helping patients with HIV and TB in low- and middle-income countries

Roche Basel Switzerland

Roche reinforces commitment to the World Federation of Hemophilia Humanitarian Aid Program

The company renewed its pledge to provide preventative treatment until 2028 for haemophilia A patients

- PMLiVE

Gilead signs $300m deal with Dragonfly to advance immunotherapies

The partnership will make use of Dragonfly’s oncology and inflammatory disease research capabilities

Roche Basel Switzerland

Roche’s Evrysdi improves survival rates for infants with SMA

The study showed the drug reduced serious adverse events and hospitalisations

- PMLiVE

Cancer Research UK drives innovation with Cancer Research Horizons

Industry partners will gain access to an extensive network of 4,000 world-leading cancer researchers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links